Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps
Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps
On Tuesday, Embecta Corp (NASDAQ:EMBC) posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents and down from 59 cents reported a year ago.
週二，Embecta 公司（納斯達克：EMBC）發佈了第四季度調整後每股收益爲45美分，超出市場共識的36美分，且較去年報告的59美分有所下降。
The company reported quarterly sales of $286.1 million, up 1.5% year over year, beating the consensus of $277 million.
該公司報告的季度銷售額爲28610萬美元，同比增長1.5%，超出市場共識的27700萬美元。
"We are pleased to report a strong fourth quarter and end to our fiscal year, as we once again delivered results that exceeded our expectations across key financial metrics...Additionally, the recent launch of our small-pack GLP-1 needles in Germany has gone well, and we are evaluating expanding into other markets," said Devdatt (Dev) Kurdikar, Chief Executive Officer of Embecta.
「我們很高興能報告強勁的第四季度和我們的財年結束，因爲我們再次在關鍵財務指標上交出了超出預期的業績……此外，我們在德國推出的小包裝GLP-1針頭進展順利，我們正在評估向其他市場擴展的可能性，」Embecta首席執行官Devdatt (Dev) Kurdikar說。
The Becton, Dickinson and Company (NYSE:BDX) spin-off announced that it decided to discontinue its insulin patch pump program and plans to initiate a restructuring plan.
貝克頓、迪金森和公司（紐交所：BDX）的分拆宣佈決定停止其胰島素貼片泵計劃，並計劃啓動重組計劃。
In July, Embecta, a manufacturer of disposable insulin pen needles and syringes, said it is considering a potential sale following a significant drop in its share price since being spun off from health tech giant Becton, Dickinson.
七月份，作爲一次性胰島素筆針和注射器的製造商，Embecta表示考慮在從醫療科技巨頭貝克頓、迪金森分拆後，股價大幅下跌的情況下潛在出售。
"We intend to concentrate our resources on our core business and to prioritize our free cash flow towards paying down debt, which we expect will give us the financial flexibility needed for future investments," Kurdikar said.
Kurdikar表示：「我們打算集中資源於我們的核心業務，並優先使用我們的自由現金流來償還債務，我們預計這將爲未來的投資提供所需的財務靈活性。」
Embecta expects between $25 million and $30 million in pre-tax, cash charges for planned workforce reductions and other associated costs from the discontinuation of its patch pump program.
Embecta預計由於計劃中的裁員和與停止其貼片泵計劃相關的其他費用，將產生2500萬到3000萬美元的稅前現金費用。
In total, Embecta expects between $35 million and $45 million in pre-tax charges in 2025 related to its restructuring plan. It anticipates completing the restructuring in the first half of 2025. Embecta projects annual cost savings of $60 million to $65 million from this restructuring.
總的來說，Embecta預計在2025年與其重組計劃相關的稅前費用在3500萬到4500萬美元之間。它預計將在2025年上半年完成重組。Embecta預計從此次重組中每年節省6000萬到6500萬美元的成本。
Given the organizational restructuring plan, the company has postponed its Analyst & Investor Day to Spring 2025.
鑑於組織重組計劃，公司已將分析師與投資者日推遲至2025年春季。
Guidance: Embecta says that for the fiscal year 2025, excluding the Patch Pump program, revenues are expected to be $1.093 billion—$1.11 billion compared to a consensus of $1.12 billion, with an adjusted EPS of $2.70—$2.90 versus the consensus of $2.27.
指導意見：Embecta表示，除了Patch Pump項目外，2025財年的收入預期爲10.93億至11.1億，與共識的11.2億相比，調整後的每股收益預期爲2.70至2.90美元，而共識爲2.27美元。
Price Action: EMBC stock is up 33.5% at $19.23 at last check Tuesday.
價格走勢：EMBC股票在週二最後檢查時上漲了33.5%，報19.23美元。
Image via Unsplash
圖片來源：Unsplash
- Why Is Exact Sciences Stock Trading Higher On Monday?
- 爲什麼精密科學的股票在週一交易價格上漲？
譯文內容由第三人軟體翻譯。
